Profitability Metrics

Gross Margin
35.19%
Operating Margin
9.90%
Net Margin
35.00%

Efficiency Metrics

Revenue per Expense Ratio
1.11
R&D as % of Revenue
1.23%

Earnings Quality

EBITDA Margin
16.19%
Income Tax Rate
15.35%
EPS
18.2100000000

Balance Sheet Analysis

Current Ratio
2.27
Cash Ratio
1.00
Working Capital
$615.80M
Debt to Equity
0.43
Debt to Assets
23.85%
Equity Ratio
54.93%

Cash Flow Analysis

Operating Cash Flow Ratio
4.46%
Free Cash Flow Ratio
1.15%
CapEx to Revenue
3.31%
Dividends Paid
$12.80M
Stock Buybacks
$5.10M
Total Shareholder Returns
$17.90M
Cash Position Change
561.15%

Key Takeaways (2023 FY)

  • Revenue declined by 23.157894736842%, indicating potential market challenges
  • Maintained positive net income growth despite revenue changes

Detailed Growth Metrics

Core Performance

Revenue
-23.16%
Net Income
324.02%
EPS
324.48%
Operating Income
-2.20%

Operational Efficiency

R&D Expenses
-30.27%
SG&A Expenses
-8.51%
Operating Cash Flow
-47.86%
Free Cash Flow
-65.08%

Balance Sheet Health

Assets
4.89%
Debt
-33.90%
Book Value per Share
72.59%
Inventory
-25.92%

Shareholder Returns

Dividends per Share
-2.29%
Shares Outstanding
0.00%

Long Term Trends

3Y Revenue/Share
-3.67%
5Y Revenue/Share
-13.57%
3Y Dividend/Share
0.00%
5Y Dividend/Share
-2.60%